ArticleBMC cancer2026
Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe objective of this research was to examine the influence of metformin on both prognosis and adverse reactions in patients who have undergone radical cystectomy (RC) and subsequently received adjuvant gemcitabine and cisplatin (GC) chemotherapy for muscle-invasive bladder cancer (MIBC).
methodsA retrospective evaluation was performed on data from 243 patients who had undergone RC followed by adjuvant GC chemotherapy at the Affiliated Hospital of Xuzhou Medical University, Xuzhou First People’s Hospital, and Xuzhou Third People’s Hospital during the period from April 2014 to April 2024. The subjects were categorized into three categories based on metformin usage: non-diabetic (No DM), type 2 diabetic with metformin use (DM + Metformin), and type 2 diabetic without metformin use (DM-Metformin). Clinical and pathological characteristics were compiled and subjected to analysis. Progression-free survival (PFS) was assessed utilizing the Kaplan–Meier technique, while Cox proportional hazards models were employed for multivariable analysis.
resultsAmong the 243 patients, diabetes was present in 68 individuals, of whom 51 were administered metformin. Pairwise comparisons revealed that diabetic patients receiving metformin exhibited significantly higher 3-year PFS rates compared to both diabetic patients not using metformin (23.6% vs. 7.2%, p = 0.007) and non-diabetic patients (23.6% vs. 13.4%, p = 0.034). In the multivariable analysis, metformin use was independently associated with a reduced risk of disease progression, both in the pooled analysis (Met vs. No Met: HR = 0.66, 95% CI 0.45–0.95, p = 0.025) and, most notably, in the direct comparison among diabetic patients (DM + Met vs. DM-Met: HR = 0.34, 95% CI 0.16–0.75, p = 0.007). Moreover, those administered metformin experienced a lower frequency of grade 3 or higher adverse reactions.
conclusionThis study provides clinical evidence suggesting that metformin use is associated with enhanced progression-free survival and a reduction in adverse reactions in patients receiving adjuvant GC chemotherapy after RC for MIBC. The beneficial association appears to be particularly pronounced in diabetic patients. These findings support the potential of metformin as an adjunctive therapy and justify further investigation in prospective trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.